BofA Reiterates BATS Buy Rating, Cites US Vapour Growth
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
british-american-tobaccobofa
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Bank of America's equity research team reiterated its Buy rating on British American Tobacco plc (BATS) on 2 June 2026. The reaffirmation underscores the bank's confidence in the tobacco giant's strategic positioning, particularly the sustained strength of its US vapour business. This analyst action provides a significant vote of confidence for investors monitoring the ongoing transition within the global tobacco industry.
The tobacco sector faces a pivotal transition as declining cigarette volumes accelerate in key Western markets. Regulatory pressures, including potential menthol bans and plain packaging laws, have pressured traditional revenue streams. BATS and its peers are navigating this shift by aggressively investing in Non-Combustible Product categories, which include vapour, tobacco heating products, and modern oral nicotine pouches. The success of these New Category segments is critical for long-term investor sentiment and valuation.
The current macro backdrop of persistent inflation places consumer staples under scrutiny for pricing power. The last major analyst action on BATS occurred in Q4 2025 when several firms expressed caution over the company's debt load following its large-scale acquisition of a competitor's vapour assets. BofA's latest reiteration signals a belief that BATS has successfully integrated these assets and is now leveraging them for measurable market share gains, making the timing of this report notable for the market.
BATS's US vapour portfolio, led by the Vuse brand, has demonstrated significant commercial traction. Vuse's retail market share in the US has grown from 32.5% in Q3 2025 to an estimated 35.1% in Q2 2026, solidifying its position as the market leader. This growth trajectory contrasts with the overall US cigarette market, which contracted by approximately 4.5% over the same period.
British American Tobacco's stock trades near a key technical level of GBP 26.50, representing a year-to-date gain of 7.2%. This performance outpaces the FTSE 100 index, which is up 2.1% YTD. BATS offers a dividend yield of 9.8%, which remains a primary attraction for income-focused investors. The company's market capitalisation stands at approximately GBP 59 billion, making it one of the largest constituents of the UK benchmark.
| Metric | BATS | Peer Average |
|---|---|---|
| Dividend Yield | 9.8% | 7.5% |
| YTD Performance | +7.2% | +3.5% |
| US Vapour Share | 35.1% | ~25% |
BofA's positive stance is a net positive for the broader consumer staples sector, particularly firms with strong exposure to reduced-risk product categories. The reaffirmation may direct institutional flow towards BATS and other tobacco equities with successful New Category strategies, such as Imperial Brands. Conversely, it presents a relative headwind for purely cigarette-dependent manufacturers lacking a credible transition plan. The analysis suggests that investor rewards will increasingly flow to companies demonstrating tangible progress in market share capture within the vapour and heated tobacco segments.
A key risk to the thesis is the ongoing regulatory uncertainty from the US Food and Drug Administration. The agency continues to review pre-market tobacco product applications, and adverse decisions on key vapour products could swiftly reverse market share gains. Despite this, positioning data indicates that long-only institutional investors have been increasing their stakes in BATS over the past quarter, betting on the sustainability of its non-combustible growth.
The next significant catalyst for BATS will be its Q2 2026 trading statement, expected on 31 July 2026. Investors will scrutinise this update for confirmation of the US vapour market share figures cited by BofA and for any revisions to full-year revenue guidance for the New Categories division. A key level to watch on the chart is GBP 27.80, a resistance level that, if broken convincingly, could signal a new bullish phase.
Market participants should also monitor the FDA's upcoming decision on the marketing status of several synthetic nicotine products, expected by Q3 2026. A restrictive ruling would benefit established players like BATS that use tobacco-derived nicotine. Any commentary from management on the potential for share buybacks, given the company's strong cash flow generation, will also be a focal point for analysts.
British American Tobacco currently offers a dividend yield of 9.8%, which is substantially higher than the FTSE 100 average of around 3.8%. This high yield is a function of the company's mature business model and significant free cash flow generation. However, the sustainability of the dividend is closely tied to the success of its pivot to non-combustible products, as declining cigarette sales could pressure cash flows over the long term.
BATS's Vuse brand has surpassed Juul to become the US vapour market leader. Vuse's market share is estimated at 35.1%, while Juul's share has declined to approximately 26%. This shift is attributed to Vuse's wider distribution, diverse product portfolio including reusable devices, and a more stable regulatory standing with the FDA compared to the ongoing challenges faced by Juul.
The primary risks include intense regulatory scrutiny, potential for adverse FDA rulings on key products, and ongoing secular decline in core cigarette volumes. Litigation remains a persistent, though less acute, threat. the capital-intensive nature of building new product categories can pressure profit margins in the short to medium term, even as it is necessary for long-term survival.
BofA's reiterated Buy rating signals conviction in BATS's ability to monetise the transition away from traditional cigarettes.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.